• 1
    Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002; 346: 122131.
  • 2
    Williams R. Global challenges in liver disease. Hepatology 2006; 44: 5216.
  • 3
    Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am. J. Med. 2006; 119: 81219.
  • 4
    Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. J. Atheroscler. Thromb. 2005; 12: 295300.
  • 5
    Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43 (2 Suppl. 1): S99112.
  • 6
    International Diabetes Institute. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. Melbourne: Health Communications Australia, 2000.
  • 7
    Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes. Rev. 2002; 3: 1416.
  • 8
    Wu YF. Overweight and obesity in China. The once lean giant has a weight problem that is increasing rapidly. BMJ 2006; 19: 3623.
  • 9
    Gu DF, Reynolds K, Wu XG et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005; 365: 1398405.
  • 10
    Fan JG, Zhu J, Li XJ et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J. Hepatol. 2005; 43: 50814.
  • 11
    Bellentani S, Saccoccio G, Masutti F et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 2000; 132: 11217.
  • 12
    Harrison SA. Liver disease in patients with diabetes mellitus. J. Clin. Gastroenterol. 2006; 40: 6876.
  • 13
    Farrell GC. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? J. Gastroenterol. Hepatol. 2003; 18: 12438.
  • 14
    Omagari K, Kadokawa Y, Masuda J et al. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J. Gastroenterol. Hepatol. 2002; 17: 1098105.
  • 15
    Hsieh SD, Yoshinaga H, Muto T, Sakurai Y, Kossaka K. Health risks among Japanese men with moderate body index. Int. J. Obes. Relat. Metab. Disord. 2000; 24: 35862.
  • 16
    Petersen KF, Dufour S, Feng J et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc. Natl Acad. Sci USA. 2006; 103: 182737.
  • 17
    Fall CHD. Non-industrialised countries and affluence. J. R. Soc. Med. 2001; 60: 3350.
  • 18
    King H, Aubert R, Herman W. Global burden of diabetes, 1995–2005: prevalence, numerical estimates and projections. Diabetes Care 1998; 21: 141431.
  • 19
    Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 3739.
  • 20
    Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J. Gastroenterol. Hepatol. 22 (in press).
  • 21
    Friis-Liby I, Aldenborg F, Jerlstad P, Rundstrom K, Bjornsson E. High prevalence of the metabolic complication in patients with non-alcoholic fatty liver disease. Scand. J. Gastroenterol. 2004; 39: 8649.
  • 22
    Younossi ZM, Gramlich T, Matteoni CA et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin. Gastroenterol. Hepatol. 2004; 2: 2625.
  • 23
    Marchesini G, Bugianesi E, Forlani G et al. Non-alcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 91723.
  • 24
    Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver disease. A feature of the metabolic syndrome. Diabetes 2001; 50: 184450.
  • 25
    Marchesini G, Brizi M, Morselli-Labate AM et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 1999; 107: 45055.
  • 26
    Petersen KF, Shulman GI. Etiology of insulin resistance. Am. J. Med. 2006; 119 (5 Suppl. 1): S1016.
  • 27
    Petersen KF, Dufour S, Feng J et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc. Natl. Acad. Sci. USA 2006; 103: 182737.
  • 28
    Farrell GC, George J, Hall PM, McCullough AJ, eds. Fatty Liver Disease; NASH and Related Disorders. Maldon, MA: Blackwell Publishing, 2005.
  • 29
    Malik A, Cheah PL, Hilmi IN, Chan SP, Goh KL. Non-alcoholic fatty liver disease in Malaysia: a demographic, anthropometric, metabolic and histological study. Chin. J. Dig. Dis. 2007; 8:5864.
  • 30
    Wong VW, Hui AY, Tsans SW et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2006; 4: 115461.
  • 31
    Tan CE, Chew SK, Ma S, Tai ES, Wai D. Can we apply the National Cholesterol Education Program Adult Treatment Panel Definition of the metabolic syndrome to Asians? Diabetes Care 2004; 27: 11826.
  • 32
    Fan JG, Zhu J, Li XJ et al. Fatty liver and the metabolic syndrome among Shanghai adults. J. Gastroenterol. Hepatol. 2005; 20: 182532.
  • 33
    Oh JY, Sung YA, Hong YS, Barrett-Connor E. Prevalence and factor analysis of metabolic syndrome in an urban Korean population. Diabetes Care 2004; 27: 202732.
  • 34
    Park HS, Han JH, Lee SY, Kim DJ, Kim SE. Prevalence of the metabolic syndrome among Korean adults according to the criteria of the International Diabetes Federation. Diabetes Care 2006; 29: 9334.
  • 35
    Adams RJ, Grande ED, Appleton S et al. Population comparison of the two clinical approaches to the metabolic syndrome. Implications of the new International Diabetes Federation consensus definition. Diabetes Care 2005; 28: 27779.
  • 36
    Saely CH, Aczel S, Koch L et al. Adult Treatment Panel III. 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. Diabetes Care 2006; 29: 9017.
  • 37
    Hamaguchi M, Kojima T, Takeda N et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann. Intern. Med. 2005; 143: 7228.
  • 38
    Fan JG, Zeng MD, Li JQ et al. Analysis of risk factors for fatty liver. Zhonghua Yixue Zazhi 1998; 32: 189.
  • 39
    Park SH, Jeon WK, Kim SH et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J. Gastroenterol. Hepatol. 2006; 21 (1 Pt 1): 13843.
  • 40
    Shen L, Fan JG, Shao Y et al. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J. Gastroenterol. 2003; 9: 110610.
  • 41
    Shimada M, Hashimoto E, Kaneda H, Noguchi S, Hayashi N. Non-alcoholic steatohepatitis: risk factors for liver fibrosis. Hepatology Res. 2002; 24: 42938.
  • 42
    Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology 1999; 30: 135662.
  • 43
    Ratziu V, Giral P, Charlotte F et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 111723.
  • 44
    Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J. Hepatol. 2005; 42: 1328.
  • 45
    Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 141319.
  • 46
    Sanyal AJ, Banas C, Sargeant C et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006; 43: 6829.
  • 47
    Kim HJ, Kim HJ, Lee KE et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch. Intern. Med. 2004; 164: 219575.
  • 48
    Park SH, Jeon WK, Kim SH et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J. Gastroenterol. Hepatol. 2006; 21: 13843.
  • 49
    Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 11321.
  • 50
    Dam-Larsen S, Franzmann MB, Christoffersen P, Larsen K, Becker U, Bendtsen F. Histological characteristics and prognosis in patients with fatty liver. Scand. J. Gastroenterol. 2005; 40: 46067.
  • 51
    Brea A, Mosquera D, Martin E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler. Thromb. Vasc. Biol. 2005; 25: 104550.
  • 52
    Villanova N, Moscatiello S, Ramilli S et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005; 24: 47380.
  • 53
    Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Survival and causes of death in patients with elevated liver enzymes associated with non-alcoholic fatty liver disease. J. Hepatol. 2006; 44 (Suppl. 2): S401.
  • 54
    Larter CZ, Farrell GC. Insulin resistance, adiponectin, cytokines in nonalcoholic steatohepatitis: which is the best target to treat? J. Hepatol. 2006; 44: 25361.
  • 55
    Targher G, Bertolini L, Poli F, Rodella S, Scala L et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005; 53: 35416.
  • 56
    Volzke H, Robinson DM, Kleine V et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J. Gastroenterol. 2005; 11: 184853.
  • 57
    Chen HLY, Janaka de Silva H, Leung NWY et al. How should we manage patients with non-alcoholic fatty liver disease in 2007? J Gastroenterol Hepatol 2007; 22 (in press).